8.25

2.35% 0.16

Atara Biotherapeutics Inc (ATRA)

Overview News Price History Option Chain Financials Why ATRA Down? Discussions Forecast

Atara Biotherapeutics Inc stock is traded at $8.25, with a volume of 53,710. It is up +2.35% in the last 24 hours and down -1.31% over the past month. Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.

Previous Close:

$8.09

Open:

24h Volume:

53,710

Relative Volume:

0.52

Market Cap:

$83.61M

Revenue:

$23.14M

Net Income/Loss:

$-9.47M

P/E Ratio:

-9.3463

EPS:

-0.8827

Net Cash Flow:

$-25.88M

1W Performance:

-3.83%

1M Performance:

-1.31%

6M Performance:

+84.41%

1Y Performance:

-32.63%

1-Day Range:

$7.81

$8.35

1-Week Range:

$7.73

$9.43

52-Week Range:

$3.92

$19.14

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Name

Atara Biotherapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

805-623-4211

Address

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Employee

Twitter

@Atarabio

Next Earnings Date

2026-08-10

Latest SEC Filings

ATRA's Discussions on Twitter

Compare ATRA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATRA Atara Biotherapeutics Inc	8.33	81.21M	23.14M	-9.47M	-25.88M	-0.8827
VRTX Vertex Pharmaceuticals Inc	514.89	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	807.61	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.05	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.65	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	361.72	39.31B	5.76B	514.49M	1.10B	4.4813

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-26	Downgrade	Canaccord Genuity	Buy → Hold
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Mizuho	Buy → Neutral
Jul-20-22	Downgrade	Citigroup	Neutral → Sell
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-13-22	Downgrade	Stifel	Buy → Hold
May-10-22	Downgrade	Citigroup	Buy → Neutral
May-13-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-09-20	Downgrade	Citigroup	Buy → Neutral
Dec-08-20	Reiterated	H.C. Wainwright	Buy
Nov-10-20	Reiterated	H.C. Wainwright	Buy
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy
Apr-23-20	Upgrade	Citigroup	Neutral → Buy
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral
Sep-27-19	Downgrade	Goldman	Neutral → Sell
Sep-16-19	Downgrade	Jefferies	Buy → Hold
Jun-04-19	Upgrade	Citigroup	Sell → Neutral
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy
Jan-23-19	Initiated	Mizuho	Buy
Apr-10-18	Initiated	JP Morgan	Overweight
Mar-16-18	Initiated	Guggenheim	Neutral
Mar-05-18	Reiterated	Jefferies	Buy
Feb-28-18	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-15-18	Downgrade	Citigroup	Neutral → Sell
Jan-03-18	Upgrade	Citigroup	Sell → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Atara Biotherapeutics Inc Stock (ATRA) Latest News

Aug 16, 2026

ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Aug 16, 2026

Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen - MarketBeat

Aug 16, 2026

Aug 15, 2026

Why (ATRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Aug 15, 2026

Aug 14, 2026

Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com Nigeria

Aug 13, 2026

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - BioSpace

Aug 13, 2026

Aug 12, 2026

Atara Biotherapeutics cuts costs 87%, extends cash runway to mid-2027 - scanx.trade

Aug 12, 2026

Is Atara Biotherapeutics Inc (ATRA) Positioned for Growth After - GuruFocus

Aug 12, 2026

Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results - MarketBeat

Aug 12, 2026

Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary - TradingView

Aug 12, 2026

Atara Biotherapeutics (NASDAQ:ATRA): What Could Today’s Update Reveal About Program Focus And Funding Discipline? - kalkinemedia.com

Aug 10, 2026